<DOC>
	<DOCNO>NCT00133315</DOCNO>
	<brief_summary>The purpose study establish Danish cohort spondylarthropathy ( SpA ) patient treat TNFalfa blocker . By follow TNFalfa block treated patient researcher want identify good biomarkers disease activity disease progression . In addition , researcher want identify predictor disease progression .</brief_summary>
	<brief_title>TNFalfa Blocking Treatment Spondylarthropathies</brief_title>
	<detailed_description />
	<mesh_term>Spondylitis</mesh_term>
	<mesh_term>Spondylitis , Ankylosing</mesh_term>
	<mesh_term>Arthritis , Psoriatic</mesh_term>
	<mesh_term>Spondylarthropathies</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<criteria>Age &gt; 18 year old Spondylarthropathies accord European Spondylarthropathy Study Group ( ESSG ) criteria Sacroiliitis Xray magnetic resonance imaging ( MRI ) Bath Ankylosing Spondylitis Disease Activity Index ( BASDAI ) &gt; 3 No sign tuberculosis ( TB ) Sufficient contraception Wish pregnancy nurse Previous treatment TNFalfa blocker Diseasemodifying antirheumatic drug ( DMARDs ) methotrexate ( MTX ) later 4 week inclusion Steroid treatment later 4 week inclusion Immunosuppressing agent later 4 week inclusion Severe infection within 3 month HIVinfection Active hepatitis B C Active latent TB Severe chronic disease Heart insufficiency ( New York Heart Association [ NYHA ] 3 4 ) Malignancy Systemic lupus erythematosus ( SLE ) SLElike disease Abuse narcotic alcohol Major psychiatric disorder</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2007</verification_date>
</DOC>